Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Panelists discuss how systemic therapy plays a crucial role in embolization-eligible hepatocellular carcinoma (HCC), ...

"The CARES-oo5 study showed a clinically meaningful and statistically significant improvement in the primary endpoint of PFS for unresectable HCC who received TACE plus immunotherapy-based ...

TACE is a treatment used for hepatocellular carcinoma, the most common type of liver cancer. Experts estimate that 90% or more of liver cancers are hepatocellular carcinomas. While most of your ...

The panelist discusses, for intermediate-stage unresectable hepatocellular carcinoma (uHCC), key clinical pearls include prioritizing transarterial chemoembolization (TACE) as a first-line therapy, ...

Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events included hypertension and anemia. Evidence ...

TACE, transarterial chemoembolization. The unit of AFP is ng/mL. With the advent of the immunotherapy era in oncology, researchers have held great expectations for immunotherapy-based adjuvant ...

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes. Among patients with unresectable, non-metastatic ...

Immunotherapy has revolutionised the treatment of advanced hepatocellular carcinoma, starting with atezolizumab–bevacizumab superseding sorafenib in the first line. But how have other areas of care ...

In a cohort of 62 patients with HCC there were 141 sessions of TACE with DEB loaded with doxorubicin. [56] At 9 months of follow-up, the sustained objective response (European Association for the ...